Search

Home > New FDA Approvals > 135 - Rubraca assay for ovarian cancer; tolvaptan in inherited kidney disorder; halting of trastuzumab biosimilar approval; FDA promotes artificial intelligence in health care
Podcast: New FDA Approvals
Episode:

135 - Rubraca assay for ovarian cancer; tolvaptan in inherited kidney disorder; halting of trastuzumab biosimilar approval; FDA promotes artificial intelligence in health care
Category: Science & Medicine
Duration: 00:09:40
Publish Date: 2018-04-27 06:00:00
Description:

April 27, 2018

 

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com 

1:11 FDA approves first assay to identify Rubraca benefit among women with ovarian cancer https://www.curetoday.com/articles/fda-approves-first-assay-to-identify-rubraca-benefit-among-women-with-ovarian-cancer

3:27 FDA OKs Otsuka's tolvaptan to slow kidney function decline in inherited kidney cyst disorder https://www.otsuka-us.com/discover/articles-1188

5:16 US FDA halts approval for Pfizer’s trastuzumab biosimilar https://www.biopharma-reporter.com/Article/2018/04/24/US-FDA-halts-approval-for-Pfizer-s-trastuzumab-biosimilar 

6:59 FDA chief moves to promote artificial intelligence in health care http://thehill.com/policy/healthcare/385020-fda-chief-moves-to-promote-artificial-intelligence-in-health-care

Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com.

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Total Play: 0